BREAKING: Opexa Initiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis (SPMS)

Opexa Therapeutics, Inc. today announced the initiation of a Phase IIb clinical trial of Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), in patients with Secondary Progressive Multiple Sclerosis (SPMS). The therapy is specifically tailored to each patient’s individual disease profile and has demonstrated superior safety and encouraging indications of efficacy in previous clinical studies in MS that included the treatment of SPMS patients.

Read more »

Ann Romney, Michelle Obama Rally For Their Ticket – And The MS Population

With the 2012 Presidential election upon us, healthcare – both as a social service and essential sector of our economy – is once again a main pillar in the heated political debate. Ann Romney and Michelle Obama, both with a direct connection to Multiple Sclerosis, have opened up to campaign supporters in recent months about the effects of this debilitating disease.

Read more »

Opexa CEO, Neil Warma Discusses a Potential Blockbuster Treatment in Numerous Autoimmune Diseases

OneMedResearch recently initiated coverage on Opexa Therapeutics, a biotechnology company developing patient-specific cellular therapies for the treatment of autoimmune diseases.

Read more »

A Busy Week for Multiple Sclerosis News

It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.

Read more »

Ampyra Walks Away with FDA Approval

The U.S. Food and Drug Administration (FDA) has approved the first drug designed to improve walking in adults with multiple sclerosis.

Read more »

Opexa Shares Soar on Multiple Sclerosis Trial Data

Opexa Therapeutics announced that 83 percent of clinical trial patients taking its therapeutic vaccine Tovaxin remained relapse-free for a year.

Read more »